Why is Bharat Immunolog falling/rising?

As of 29-Jul, Bharat Immunological & Biological Corporation Ltd is currently priced at 22.63, reflecting a slight increase of 0.03 or 0.13%. Despite this minor uptick, the stock has been underperforming, as evidenced by its performance today, which lagged behind its sector by 1.28%. The stock has experienced a trend reversal, gaining after two consecutive days of decline. However, it is trading below all its moving averages, indicating a bearish trend. Additionally, the stock has seen a significant drop in investor participation, with delivery volume falling by 58.86% compared to the five-day average. Over the past year, the stock has generated a return of -33.44%, highlighting its poor performance relative to the broader market.
In the broader market context, Bharat Immunological has underperformed the Sensex, which has shown a decline of 1.03% over the past week, while the stock itself has decreased by 0.44%. The company's weak long-term fundamentals, including a lack of declared results in the last six months and a significant decline in net sales and operating profit, contribute to its negative outlook. The high debt to EBITDA ratio further complicates its financial stability. With a recent report indicating a substantial drop in net sales and profit after tax, the stock's risk profile has increased, making it less attractive to investors. Overall, the combination of poor financial performance and declining investor interest has led to the stock's recent struggles.